ArticleScientific reports2016
Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 91 citations in OpenAlex.
- Mechanistic insights into piperlongumine's neuroprotective role against cisplatin-induced neuropathy: a network pharmacology, molecular dynamics, and experimental approach.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Migrasomes: A Novel Target for Cancer Treatment.Current cancer drug targets · 2026Review
- Synthesis, anticancer evaluation, preliminary mechanism study of novel 1, 2, 3-triazole-piperlongumine derivatives.Molecular diversity · 2025Article
- The context-dependent effect of cellular senescence: From embryogenesis and wound healing to aging.Ageing research reviews · 2025Review
- NF-Journal of immunology research · 2025Article
- Article
- Piperlongumine induces apoptosis via the MAPK pathway and ERK‑mediated autophagy in human melanoma cells.International journal of molecular medicine · 2023Article
- The Antitumor Activity of Piplartine: A Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The role and implication of autophagy in cholangiocarcinoma.Cell death discovery · 2023Review
- "Double-edged sword" effect of reactive oxygen species (ROS) in tumor development and carcinogenesis.Physiological research · 2023Review
- Piperlongumine Induces Cellular Apoptosis and Autophagy via the ROS/Akt Signaling Pathway in Human Follicular Thyroid Cancer Cells.International journal of molecular sciences · 2023Article
- Molecular Modeling and In Vitro Evaluation of Piplartine Analogs against Oral Squamous Cell Carcinoma.Molecules (Basel, Switzerland) · 2023Article
- Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.Frontiers in immunology · 2022Article
- Unravelling the Interaction of Piperlongumine with the Nucleotide-Binding Domain of HSP70: A Spectroscopic and In Silico Study.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Annexin A1 Mimetic Peptide and Piperlongumine: Anti-Inflammatory Profiles in Endotoxin-Induced Uveitis.Cells · 2021Article
- Article
- Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation.Molecules (Basel, Switzerland) · 2021Article
- Piperlongumine promotes death of retinoblastoma cancer cells.Oncotarget · 2021Article
- Piperlongumine targets NF-κB and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer.Molecular and cellular biochemistry · 2021Article
- Piperlongumine inhibits the growth of non-small cell lung cancer cells via the miR-34b-3p/TGFBR1 pathway.BMC complementary medicine and therapies · 2021Article
Corrections and comments
- Retraction · 2025-04-30Concerns/Issues about Image · Lack of IRB/IACUC Approval and/or Compliance · Original Data and/or Images not Provided and/or not Available · Unreliable Data ·
- Retracted
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Piperlongumine has anti-cancer activity in numerous cancer cell lines via various signaling pathways. But there has been no study regarding the mechanisms of PL on the lung cancer yet. Thus, we evaluated the anti-cancer effects and possible mechanisms of PL on non-small cell lung cancer (NSCLC) cells in vivo and in vitro. Our findings showed that PL induced apoptotic cell death and suppressed the DNA binding activity of NF-κB in a concentration dependent manner (0-15 μM) in NSCLC cells. Docking model and pull down assay showed that PL directly binds to the DNA binding site of nuclear factor-κB (NF-κB) p50 subunit, and surface plasmon resonance (SPR) analysis showed that PL binds to p50 concentration-dependently. Moreover, co-treatment of PL with NF-κB inhibitor phenylarsine oxide (0.1 μM) or p50 siRNA (100 nM) augmented PL-induced inhibitory effect on cell growth and activation of Fas and DR4. Notably, co-treatment of PL with p50 mutant plasmid (C62S) partially abolished PL-induced cell growth inhibition and decreased the enhanced expression of Fas and DR4. In xenograft mice model, PL (2.5-5 mg/kg) suppressed tumor growth of NSCLC dose-dependently. Therefore, these results indicated that PL could inhibit lung cancer cell growth via inhibition of NF-κB signaling pathway in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.